FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely, to an application of a pharmaceutical composition for treating COVID-19 and a method for treating COVID-19. The method for treating COVID-19 includes administration of a therapeutically effective amount of a pharmaceutical composition containing a therapeutically effective amount of human alpha-1-antitrypsin (AAT), a pharmaceutically acceptable excipient, and/or a carrier to a subject in need thereof, wherein said administration is performed in parallel with standard treatment of COVID-19 and complications associated with COVID-19. Application of a pharmaceutical composition containing a therapeutically effective amount of human alpha-1-antitrypsin (AAT), a pharmaceutically acceptable excipient, and/or a carrier for treating COVID-19 in parallel with standard treatment of COVID-19 and complications associated with COVID-19.
EFFECT: above solution allows for effective application of AAT for complex therapy of COVID-19.
40 cl, 8 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
| ALPHA-1-ANTITRYPSIN FOR TREATING EPISODES OF PULMONARY DISEASE AGGRAVATIONS | 2007 |
|
RU2472524C2 |
| COVID-19 (SARS-COV-2) COMBINATION THERAPY AND TREATMENT METHOD | 2020 |
|
RU2745986C1 |
| COMPOSITIONS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) | 2019 |
|
RU2804764C2 |
| PHARMACEUTICAL KIT FOR COMBINATION THERAPY OF COVID-19 (SARS-COV-2) AND METHOD OF ITS APPLICATION | 2020 |
|
RU2746161C1 |
| ANTI-CORONAVIRUS AGENT FOR COVID-19 COMBINATION THERAPY (SARS-COV-2) | 2020 |
|
RU2742116C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| METHODS OF TREATING DISEASES ASSOCIATED WITH S1P1 RECEPTOR | 2021 |
|
RU2821032C1 |
| METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME BY DALARGIN AND A PULMONARY SURFACTANT | 2020 |
|
RU2728821C1 |
